Market Cap 289.94M
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,122,400
Avg Vol 651,766
Day's Range N/A - N/A
Shares Out 47.22M
Stochastic %K 100%
Beta N/A
Analysts Strong Sell
Price Target $23.80

Latest News on ALMS

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 2 months ago

Alumis Strengthens Leadership Team with Key Appointments


Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 6 months ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?


Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 9 months ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut


Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 9 months ago

Alumis Announces Pricing of Initial Public Offering


Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 10 months ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO


Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 10 months ago

Alumis eyes $300 million in proceeds in IPO


Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

Jun 11, 2024, 12:25 PM EDT - 10 months ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results